OPEN COOPERATION
Overseas cooperation with top scientists with successful experience in developing innovative drugs
KERUN SURVEY
2005
Founded In Chongqing
CHARACTERISTIC LEADING
Efficient large-scale refolding technology and long-term drug technology
SUCCESSFUL DEVELOPMENT
5 new biological drugs and 10 + drugs selected after research
DRUG R & D PLATFORM
DRUG DEVELOPMENT STRATEGY
Relying on the national biological macromolecular drug pilot test platform and based on the expression system of E. coli and yeast, a number of mature core technologies with independent characteristics have been established, which can help support the development of commercially valuable products with market competitiveness, and a number of international first imitation biological drugs with market monopoly have been developed. At present, Kerun is implementing innovation transformation, cooperating with overseas top scientists with successful experience in developing innovative drugs, and carrying out cooperation in innovative biological drugs and platform construction
The company's products are positioned in subdivided fields, adhere to the road of differentiation, guided by clinical needs and relying on mature platform technology, and is committed to developing innovative and efficient high-quality biological drugs that can fill the domestic gap and can be reached by patients
OPHTHALMIC DRUGS
Focusing on the development of ophthalmic biological macromolecular drugs, the layout on the product pipeline covers fundus retinal vascular diseases, dry eye, keratitis, non infectious uveitis and other diseases in the field of ocular surface. Develop multiple drugs for one disease. One drug should have iterative drugs as much as possible to ensure the success rate of development.
OTHER PROTEIN DRUGS
At present, the company also has a product layout in the fields of treating malignant tumors, cardiovascular and cerebrovascular diseases, metabolism and other diseases. Among them, the self-developed domestic exclusive class 1 new drug recombinant carboxypeptidase G2 for injection, which is urgently needed in clinic, has been under phase II and III combined clinical research in Peking Union Medical College Hospital. This product is intended to apply for the conditional listing of clinically urgently needed drugs. In terms of innovative drugs, ADC drugs and long-acting drugs for the treatment of leukemia, lymphoma and other blood tumors, which have been cooperated with foreign scientists with successful development experience of a variety of innovative drugs, have also completed the molecular concept verification. This project is positioned as the first in class innovative drug project.
PRODUCT DEVELOPMENT
NEWS
|
|
GATHERING ELITES
Kerun takes talent construction as the core, constantly attracts talents and encourages innovation.
Here, you get not only a job, but also a platform to give full play to your potential and realize your personal value.